KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Financing Activities (2016 - 2025)

Neogenomics (NEO) has disclosed Cash from Financing Activities for 16 consecutive years, with $431000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 37.26% year-over-year to $431000.0, compared with a TTM value of -$200.3 million through Dec 2025, down 4410.98%, and an annual FY2025 reading of -$200.3 million, down 4410.98% over the prior year.
  • Cash from Financing Activities was $431000.0 for Q4 2025 at Neogenomics, down from $765000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $524.9 million in Q1 2021 and bottomed at -$202.4 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $27.3 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities soared 84978.61% in 2021, then tumbled 10396.69% in 2025.
  • Year by year, Cash from Financing Activities stood at $2.5 million in 2021, then fell by 26.75% to $1.8 million in 2022, then dropped by 29.52% to $1.3 million in 2023, then tumbled by 45.91% to $687000.0 in 2024, then plummeted by 37.26% to $431000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for NEO at $431000.0 in Q4 2025, $765000.0 in Q3 2025, and -$202.4 million in Q2 2025.